Aida Pharmaceuticals Wins Lawsuit Against Counterfeit Drug Suppliers
HANGZHOU, China, Feb. 1 /PRNewswire-FirstCall/ — Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA – News), one of mainland China's leading pharmaceutical companies, today announced the Company has won an infringement lawsuit against four counterfeit drug suppliers of the transfusion form of Etimicin Sulfate, Aida Pharmaceuticals' patented antibiotic.
The ruling was handed down by the Intermediate Court of Hainan and demands that the four companies terminate all manufacturing, marketing and promotional activities of the counterfeit transfusion form of Etimicin Sulfate. Additionally, the companies must destroy all remaining counterfeit products in stock and all marketing material in circulation, including any collateral on the Internet, issue a statement of apology to Hainan Aike Pharmaceutical Co., Ltd, one of Aida's subsidiaries, and compensate Aike US$77,180 (RMB 600,000).
1 February 2007